Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556956 | 0.89 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29456842 | 0.87 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL10110895 | 0.87 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28309128 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15874406 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15874638 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29823515 | 0.85 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8453047 | 0.85 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL23918256 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL12128707 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | KMT2A 397/4885FABP5 1955/4885FABP7 831/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | KMT2A 397/4885FABP5 1955/4885FABP7 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.